Autolus Therapeutics Plc

Autolus Therapeutics plc a clinical-stage biopharmaceutical company develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22 which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4 a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG a programmed T cell investigational therapy which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8 a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5 a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London the United Kingdom.